

18-20 November | Frankfurt, Germany

www.ehs-biopharma-europe.com

REGISTER BY
FRIDAY, 1 AUGUST
TO SAVE UP TO
€1,100



EHS for Biopharma Summit **EUROPE**

Manage Risk & Ensure Compliance in Lab & GMP Environments

Minimise Occupational Risks, Optimise Industrial Hygiene Standards & Foster a Safety-Minded Culture Across R&D & Manufacturing Facilities

Expert Speakers Include:



David Revitt
Director EHS & Sustainability
Vertex Pharmaceuticals



Andrew King
Senior Director HSE
AstraZeneca



Ines Quinty
Global EHS Director
Ipsen



Lasse Kragh
Anderson
Safety Director
Novo Nordisk



Christian Bugl
Head of EHS
Takeda



Rocco Alberto Ricci
EHS Associate
Director
AbbVie

■ It was great to have industry specific EHSS professionals from a range of different sized companies and in varying states for their programs and initiatives. ■

Senior EHSS Coordinator, **Forge Biologics**

*Testimonial from Hanson Wade's EHS for Biopharma West Coast Event 2024

+44 (0)20 3141 8700 @ info@hansonwade.com

www.ehs-biopharma-europe.com [in](#) Prioritize EHS



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Europe's First Industry-Specific Safety Initiative for Biotech & Pharma

EHS for Biopharma Summit EUROPE
18-20 November, 2025
Frankfurt, Germany

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

As the biopharmaceutical industry continues to evolve through rapid growth and innovation, the importance of robust Environment, Health & Safety (EHS) practices has never been greater. Safely handling novel drug modalities, controlling occupational exposure to APIs, and fostering a proactive safety culture across expanding workforces are now critical priorities for organisations striving to stay compliant and competitive.

To address these challenges head-on, Europe's first **EHS for Biopharma Summit** has been uniquely designed to provide sector-specific benchmarking and actionable insights. Bringing together EHS leaders from big pharma, emerging biotech, CDMOs, and more, this collaborative forum will explore the tactical and operational application of EHS best practices across pharma and biopharma environments.

Over three days, engage in cutting-edge discussions and real-world case studies that will equip you with practical strategies to implement immediately, including:

- Assessing risks of novel drug modalities, enhancing biosafety protocols, and managing hazardous biopharma waste
- Building a safety-minded culture across both individual sites and global operations
- Navigating complex regulatory landscapes to ensure compliance across European sites
- Leveraging next-generation technologies to shape the future of EHS

Join **80+ Global EHS Leaders, Directors, Site Heads, VPs, and Managers**, from companies such as **AstraZeneca, Vertex Pharmaceuticals, AbbVie**, and **Novo Nordisk** as they share insights, tackle shared challenges, and work towards a zero-incident future across R&D and manufacturing facilities.

What Your Peers Have to Say

“This experience really sticks out. First was that the event was smaller, which gave it a more intimate feel. Second, the collection of people who attended was amazing. A great group of people in the field.”

Staff EHS Specialist,
Dexcom

“This was an excellent opportunity to network with others in the EHS field. I appreciate the sharing of information and roundtable discussions.”

Senior EHS Program
Manager, **Genentech**

**From Past Attendees at EHS for Biopharma Summit US*

Key Benefits of Attending



Access Exclusive Insights from Industry Leaders

Gain exclusive insights from EHS leaders at AstraZeneca, Novo Nordisk, Regeneron, and AbbVie as they tackle today's toughest challenges across global R&D and manufacturing.



Tackle Today's Critical EHS Risks Head-On

Learn best practices for safely managing novel drug modalities, controlling occupational exposure to APIs, and minimising industrial hygiene risks in both lab and GMP environments.



Boost Compliance & Regulatory Confidence Across Europe

Understand how to effectively navigate evolving European EHS regulations, ensuring full compliance across all your sites while reducing risk and maintaining operational efficiency.



Future-Proof Your EHS Strategy with Cutting-Edge Technologies

Explore how AI is transforming EHS workflows, with a dedicated workshop and discussions designed to equip your team with the tools to innovate safely and effectively.



Strengthen Your Safety Culture & Drive Organisational Change

Discover how to foster a culture of safety, equity, and accountability, both at individual sites and across your entire organisation, empowering teams and reducing incidents across the board.

Your Expert Speakers

 **EHS for Biopharma
Summit EUROPE**
18-20 November, 2025
Frankfurt, Germany

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



Rocco Alberto Ricci
EHS Associate Director
AbbVie



Tomas Schou Winther
Director, EHS
AGC Biologics



Kirk Smith
Principal, Safety & HOP
Practitioner
Alkermes



Andrew King
Senior Director HSE,
Sustainability & Quality
Control IT Systems
AstraZeneca



Laurent Seurin
Senior Director, Safety,
Health and Environment
(Cambridge Operations
and UK SHE Lead)
AstraZeneca



Dirk Schreiber
Associate Director EHS
Ferring Pharmaceuticals



Fuad Mahmood
Global EHS Director
Grünenthal Group



Inès Quinty
Global EHS Director
Ipsen



Ben Cunningham
EHS Director
**Oxford Nanopore
Technologies**



Claudio Matos
EHS & AI Professional
Oxford University



Lasse Kragh Anderson
Safety Director
Novo Nordisk



Mary Fahy
Senior Manager EHS,
Regeneron



Michael Wachala
Associate Director of EHS
Regeneron



Christian Bugl
Head of EHS,
Sustainability, Ethics &
Compliance
Takeda



Artūras Gečys
Senior Manager EHS
Thermo Fisher Scientific



David Revitt
Director EHS&S
Vertex Pharmaceuticals

“I enjoyed the number of participants - it was small enough to be able to engage with everyone and make a lot of connections and have open dialogues. I also enjoyed the mix of presentations vs round tables. It kept things fun, and people engaged.”

Senior Manager, Environmental, Health, Safety & Sustainability, **Kite Pharma**

**From Past Attendees at the US EHS for Biopharma Events*

Pre-Conference | Workshop Day

Tuesday, 18 November 2025

EHS for Biopharma
Summit EUROPE
18-20 November, 2025
Frankfurt, Germany

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Check In, Coffee & Light Breakfast

7.00

Workshop A

8.00

Unlocking Value at the Intersection of EHS, Manufacturing Optimisation & Sustainability

As pharma and biotech organisations face pressure to increase productivity through AI, automation, and headcount reduction, there's a growing need to connect the dots between EHS, continuous manufacturing, and sustainability. This closing panel will explore how aligning these areas can unlock operational value, enhance safety, and support long-term strategic goals.

Key Questions to Be Addressed:

- How can EHS leaders play a strategic role in productivity and transformation programs driven by AI and continuous manufacturing?
- What are the risks of overlooking EHS and sustainability in efforts to reduce FTEs and increase automation?
- How can organisations practically align safety, efficiency, and sustainability goals to realise measurable benefits?
- What leadership behaviours and structures are needed to bridge operational and EHS functions effectively?

Workshop Leaders



Andrew King
Senior Director
HSE, Sustainability
& Quality Control
IT Systems
AstraZeneca



Laurent Seurin
Senior Director,
Safety, Health and
Environment
AstraZeneca

Morning Break & Refreshments

11.00

Workshop B

11.15

Shaping AI in EHS: Opportunities, Limitations, & System Thinking Approach

This workshop is designed for leaders seeking practical insights into strategically integrating AI into EHS. We will address AI's potential, deal with its practical challenges, and explore how it is connected within a holistic systems framework.

Highlights include:

- Explore AI's vision and Realities
- Implement effective governance & manage risks
- Connect the dots with a system approach

*There will be a 30 minute break for lunch to be served during this workshop.

Workshop Leaders



Claudio Matos
EHS & AI
Professional
Oxford University

Afternoon Break & Refreshments

2.45

Workshop C

3.00

Enhancing Top-Down Leadership Accountability to Streamline Communication & Empower Safety Culture

Despite evolving regulations and increasing complexity in biopharma, this workshop emphasises that effective safety leadership must come from the top, not just the EHS department. Join us to explore practical strategies for building leadership accountability across all levels of the business.

Highlights include:

- How biopharma companies are shifting from EHS as a legal requirement to EHS as a leadership competency
- Creating safety leadership programs (e.g., behaviour-based safety, life-saving rules, leadership walk-throughs) that stick
- Building capability: Making sure senior leaders know not just what to do, but why it matters
- How visible, values-driven leadership in safety can strengthen trust, improve culture, and boost performance
- Benchmarking how top companies respond to incidents and how leadership presence makes or breaks safety culture

Workshop Leaders



Mary Fahy
Senior Manager
EHS
Regeneron



Fuad Mahmood
Global EHS
Director
Grunenthal Group

End of Preconference Workshop Day

6.00

“Able to engage with everyone, make a lot of connections and have open dialogues. I enjoyed the mix of presentations vs round tables. It kept things fun, and people engaged.”

Senior Manager EHS&S, **Kite Pharma**

*From Past Attendees at the US EHS for Biopharma Events

Conference Day One

Wednesday, 19 November 2025



8.00 Check In, Coffee & Light Breakfast

8.55 Chair's Opening Remarks

Developing, Supporting & Sustaining the Human Side of EHS



Christian Bugl

Head of EHS,
Sustainability, Ethics &
Compliance
Takeda



Tomas Schou Winther

Director Environment
Health Safety
AGC Biologics

9.00 **Panel Discussion: Non-Technical Skills: Developing the Human Skills for EHS Leadership**

In many companies, EHS professionals rise through the ranks based on technical expertise without developing the technical skills for leadership. This session explores how we develop the non-technical skills that truly define leadership: influence, communication, empathy, strategic thinking, and the ability to connect EHS goals with business outcomes. We'll also tackle a hard truth, not every great EHS expert wants or is ready for leadership. So how do we identify, support, and shape those who are?

- Why do we keep promoting technical experts into leadership without leadership development?
- How do we differentiate between technical specialists who want to go deep vs. those who want to lead?
- What kind of development programs, coaching, or mentorship actually help build leadership capacity?
- Are we helping the people closest to the work do their jobs better?

9.45 **How Can Diversity, Generational Mix, & a Speak-Up Culture Enhance Workplace Safety & Reduce Deviations?**

In the modern workplace, retaining qualified EHS professionals is no longer just about offering competitive salaries; it's about creating an environment that addresses the diverse psychological, social, and generational needs of employees. With recruitment pipelines narrowing and attention spans shortening, organisations must adapt both their communication styles and benefits offerings.

- Developing retention strategies that consider the different values and expectations of multi-generational teams: flexible working arrangements and mental health support for younger employees, as well as diversity, values, stability, recognition, and long-term incentives for experienced staff
- By actively addressing psychosocial risks, leadership engagement, and communication quality, organisations can foster psychological safety and connection. These are critical for performance, innovation, and sustainability—engaged employees become the most valuable asset in achieving EHS excellence. Beyond a healthy error culture, a lived speak-up culture must also be defined as a core value

Building internal capabilities and securing the team's future: instead of relying solely on a shrinking talent pool, companies should invest in structured development pathways for current employees. Upskilling and cross-functional training enhance employee retention, strengthen loyalty, and reduce turnover while preparing the team for future challenges. Effective generational management is essential to combine existing knowledge and new, creative approaches into added value.



Christian Bugl

Head of EHS,
Sustainability, Ethics &
Compliance
Takeda

Conference Day One

Wednesday, 19 November 2025



10.15 Roundtable: Adapting Training Across Generations, Languages & Learning Styles

This session will start with a 10 minute presentation followed by a round table. From language barriers to generational differences in how people learn and engage, global teams need training that resonates with everyone. This session explores inclusive, adaptable safety training, what works across borders, what gets lost in translation, and how we design training that feels personal, not generic. More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas:



Andrew King
Senior Director HSE,
Sustainability & Quality
Control IT Systems
AstraZeneca

How do communication preferences change training effectiveness and how can we reach a multigenerational workforce?

What techniques drive employee engagement in remote or hybrid EHS training?

How do you design scalable training that adapts to different risk profiles and regulatory contexts and how can global standards be localised?

Moderator Feedback & Audience Debate

Moderators will be assigned to each roundtable to facilitate discussion and collate the findings. Following the roundtable discussions, they will present back to the entire delegation and open wider audience debate.



11.00 Speed Networking

The ideal opportunity to get face-to-face with many of the brightest minds in EHS for Biopharma to engage with attendees for important in-depth conversations



11.30 Morning Break & Refreshments

Navigating Regulatory Complexity & Supply Chain Risk in Europe



Rocco Alberto Ricci
EHS Associate Director
AbbVie

12.00 Learning how to Bridge EU Environmental Directives & Site-Level Compliance to Enable Quick Decisions

- Practical implications of evolving EU directives (Urban Wastewater, Water Framework Directive)
- Cost, resource, and license burden of compliance at site level
- Importance of early site awareness vs. late corporate trickle-down

Conference Day One

Wednesday, 19 November 2025



12.30 Roundtable: Understanding the Differences in Regulations to Facilitate the Harmonisation of EHS Standards Across Borders & Business Units

- Case examples of misalignment between corporate standards and legal mandates

More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas:

Post-Brexit UK import/export regulatory burdens

Navigating local (Italy, Germany, France) vs. corporate vs. EU-level EHS requirements

Strategies for integrating GMP, EHS, and quality compliance

Moderator Feedback & Audience Debate

Moderators will be assigned to each roundtable to facilitate discussion and collate the findings. Following the roundtable discussions, they will present back to the entire delegation and open wider audience debate.



Inès Quinty
Global EHS Director
Ipsen



David Revitt
Director EHS&S
Vertex
Pharmaceuticals



1.00 Lunch & Networking Break

Psychosocial Influences: Shaping the Future of EHS

2.00 Beyond 'Safety First': Aligning EHS with the Mission to Deliver Life-Saving Medicine: Safety is Not the Goal, it is the Enabler

- Learn how to align safety culture with purposeful action: reframe safety as part of the drug development mission
- Safety is foundational and when integrated properly, it empowers seamless, compliant, and high-performing operations
- Consider treating safety as an operational strength to enable faster decision-making, smarter risk management, and ultimately, the ability to bring medicines to patients faster without compromising ethics or compliance



Laurent Seurin
Senior Director,
Safety, Health and
Environment
AstraZeneca

2.30 Strategies to Build Industrial Hygiene Capability Across EHS Teams

Industrial hygiene and ergonomics are often the most technical and most misunderstood areas of EHS in biopharma. As sites grow more complex and regulatory expectations increase, many organisations are feeling the pressure of capability gaps at both site and regional levels.

This session offers a fresh look at how biopharma companies are addressing this shortfall, what is working and not working and demonstrates how to build industrial hygiene expertise.

- Learn how companies are building regional or "hub and spoke" IH support systems, where experts guide multiple sites, provide targeted coaching, and act as strategic partners rather than just compliance checkers
- Discover how organisations are breaking down IH into practical, role-relevant knowledge for site EHS teams and operations
- Learn how companies are applying high-impact training formats (like microlearning and job shadowing) to close the knowledge gap sustainably, especially for ergonomics and IH in cross-functional teams



Michael Wachala
Associate Director of
EHS
Regeneron

Conference Day One

Wednesday, 19 November 2025

3.00 Designing with Human Nature in Mind to Improve Mental Health & Efficiency



Inès Quinty
Global EHS Director
Ipsen

- Focusing on why the mistake made sense in the moment: rather than who made it allows organisations to learn, improve, and build psychological safety
- Creating environments, processes, and tools that support real-world decision-making, reduce cognitive load, and make the safest action the easiest to take
- Encouraging near-miss reporting, implement learning reviews instead of investigations, and train leaders to respond with curiosity over blame



3.30 Afternoon Break & Refreshments

Industrial Hygiene: Applying IH, Dealing with Exposure & Finding Solutions

4.30 Toxicology & Conjugates, New Modalities & Unfamiliar Compounds: Working with Interdisciplinary Teams



Michael Wachala
Associate Director of
EHS
Regeneron

- Early engagement between toxicology and R&D teams is becoming essential as advanced therapeutics like trispecific mAbs, ADCs, and radio conjugates become more prevalent, ensuring safety considerations are embedded from the start
- Streamlining toxicological assessment in a fast-evolving therapeutic landscape when a compound is both biological and a high potency small molecule: Are industrial hygiene and toxicology teams working together?
- Cross-functional collaboration between industrial hygiene and toxicology is critical to efficiently assess the risks of complex compounds that combine biological and high-potency characteristics
- Moving beyond default worst-case assumptions enables smarter innovation, with more nuanced, evidence-based toxicity assessments that balance safety with scientific progress

5.00 EHS Journey: Navigating the Challenges and Opportunities from Start-up to PLC



Ben Cunningham
EHS Director
**Oxford Nanopore
Technologies**

Discover the real-world experience of building an effective Environmental, Health, and Safety (EHS) program from the ground up. This presentation highlights key lessons learned, what strategies have driven success, and common pitfalls to avoid. Gain practical insights on how ONT is navigating the journey and what approaches they have used to try to embed a strong safety culture, ensuring sustainable operational excellence every step of the way through the integration of EHS into business operations.

5.30 Chair's Closing Remarks

“I was able to connect with colleagues in a meaningful way due to the smaller size of the conference. The presentations and discussions were relevant and informative.”

CEO, ESGineering Consulting

**From Past Attendees at the US EHS for Biopharma Events*

Conference Day Two

Thursday, 20 November 2025

EHS for Biopharma
Summit EUROPE
18-20 November, 2025
Frankfurt, Germany

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



8.00 Check In, Coffee & Light Breakfast

8.55 Chair's Opening Remarks

Novel Technologies & AI: How Much Can it Help in EHS & Biopharma?



9.00 **Roundtable: From Prediction to Prevention: AI, Automation & Risk Modelling in the Biopharma Supply Chain: What does AI-augmented risk management really look like in the supply chain?**

More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas:

Predictive safety: How companies are using near miss data, CCTV analytics, and learning systems to anticipate incidents before they happen

Automation - how are new systems changing roles?

How data is being used to forecast delivery, disruption and downstream quality risk and can AI reduce the time spent on admin-heavy assessments?

Moderator Feedback & Audience Debate

Moderators will be assigned to each roundtable to facilitate discussion and collate the findings. Following the roundtable discussions, they will present back to the entire delegation and open wider audience debate.



Inès Quinty
Global EHS Director
Ipsen



David Revitt
Director EHS&S
Vertex
Pharmaceuticals

9.45 **Balancing Documentation & Compliance with Engaging, Effective Learning**

In regulated industries like pharma and biopharma, training is often built to meet audit standards, not human memory but is a "read-and-sign" policy truly effective when 10% retention is the best-case scenario? This session explores how to balance regulatory compliance with human-centred, high-retention training that actually helps prevent injuries and improve safety.

- How can we redesign training for impact, not just records?
- Are your highest-risk tasks getting the most effective training?
- Evaluating "read-and-sign" necessary or obsolete?
- Discussing real examples of digital, blended, and peer-based training formats that work under compliance pressure



10.15 Morning Break & Refreshments

Conference Day Two

Thursday, 20 November 2025

Design Safer, Smarter Workplaces: How Modern Occupational Health Boosts Performance in Biopharma



Kirk Smith
Principal, Safety &
HOP Practitioner
Alkermes

11.15 Embedding Human Organisational Performance in Occupational Health to Foster a Culture of Trust & Collaboration

Traditional occupational health systems often emphasise compliance, reporting, and error prevention. HOP (Human and Organisational Performance) helps organisations move away from what went wrong. In this presentation, EHS, occupational health, and operations leaders explore how HOP is reshaping workplace safety and health across labs, manufacturing, and corporate offices.

- How “right the first time” messaging conflicts with human performance principles
- Practical examples of moving from blame to learning in pharma environments
- Integrating HOP into incident investigations, near miss reporting, and occupational health programs
- How HOP can reduce stress and improve trust among multi-generational workforces



11.45 Roundtable: Labs, Offices & Generations: Evolving Models to Deal with the Ever-Changing Landscape

Occupational health needs aren't one-size-fits-all. Lab workers face chemical exposure and repetitive strain, while office-based staff report increasing rates of stress, burnout, and ergonomic issues. Add to that the generational divide where younger employees expect psychological safety and flexibility, while older cohorts may prioritise privacy or legacy support systems.

More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas:

**Designing programs that appeal to Gen Z and Millennials,
Gen X and Boomers**

**Ergonomic strategies for both lab and hybrid office workers and
“standardisation” of OH services incorporating site-specific needs**

**Mental health and psychosocial support in high-pressure
lab settings vs. office settings**



David Revitt
Director EHS&S
Vertex
Pharmaceuticals

Moderator Feedback & Audience Debate

Moderators will be assigned to each roundtable to facilitate discussion and collate the findings. Following the roundtable discussions, they will present back to the entire delegation and open wider audience debate.



David Revitt
Director EHS&S
Vertex
Pharmaceuticals

12.30 Panel Discussion: Partnering with HR: Rethinking Occupational Health for a New workforce

As occupational health expands beyond physical safety to include mental well-being, inclusion, and work-life balance, cross-functional collaboration with Human Resources (HR) is becoming essential but these partnerships are not always easy or common

- Why are traditional EHS-led occupational health models no longer enough?
- Shared ownership: who drives change: EHS, OH, or HR?
- Discussions regarding tools for data sharing and mutual accountability



Kirk Smith
Principal, Safety &
HOP Practitioner
Alkermes

Conference Day Two

Thursday, 20 November 2025



1.00 Lunch & Networking Break

EHS Infrastructure & Good Practise: Upscaling & Management



Rocco Alberto Ricci
EHS Associate Director
AbbVie



Kirk Smith
Principal, Safety &
HOP Practitioner
Alkermes

2.00 Panel Discussion: Process Safety in the Age of Large-Scale Biopharma

Once viewed as low risk compared to small molecule production, bio sites are now operating 15K+ bioreactors, vast solvent systems, and steam infrastructure once unthinkable in biologics. And yet, many sites still fall outside of formal process safety rigor

This panel tackles the growing disconnect between perceived and actual risk in modern biopharma, and how organisations are responding by applying process safety standards, KPIs, and culture to these “new old risks”.

- When is a biologics site no longer a “low risk” facility? Learn how to close the gap between infrastructure scale and safety oversight
- Applying PSM selectively: hazard-based vs blanket standards and how do different companies approach biopharma site PSM adoption?
- How KPIs mislead: lagging vs leading, and what’s actually useful, are we measuring the wrong things? Explore how other firms are redefining KPIs that reflect current realities, not just historical assumptions
- Identify which process safety elements are essential to modern biologics sites, even if you are not Seveso



2.30 Roundtable: Scaling Up EHS & Manufacturing Operations: Embedding EHS Excellence into Rapid Biopharma Growth

Presentation (10/15 mins) followed by roundtable: As CDMOs and manufacturing operations rapidly scale, many sites face the pressures of operating high-mix, high-volume facilities while building an EHS organisation to match.

More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas:

The EHS role is becoming more complex and diverse: how to manage for the new normal?

How do we maintain compliance and culture with general-purpose equipment and shifting products?

Ensuring safe operations during scale-up and change



Lasse Kragh Andersen
Director, Health &
Safety
Novo Nordisk

Moderator Feedback & Audience Debate

Moderators will be assigned to each roundtable to facilitate discussion and collate the findings. Following the roundtable discussions, they will present back to the entire delegation and open wider audience debate.



3.15 Afternoon Break & Refreshments

Conference Day Two

Thursday, 20 November 2025

Building Smarter Training to Protect Teams, Pass Audits & Power Safer Science

3.45 Embedding Safety into Business DNA: How to Assess and Strengthen a “Non-Measurable” Safety Culture to Enable Real Transformation



Dirk Schreiber
Associate Director EHS
Ferring
Pharmaceuticals

Major industrial incidents repeatedly demonstrate that the prevailing safety culture is often the decisive success - or risk - factor. At the same time, studies show that organisations with a strong, mature safety culture are not only safer but also more profitable and resilient.

This presentation offers a practical approach to systematically assess the current state of your unique safety culture — even though culture is inherently “hard to measure” — and to translate this assessment into concrete strategies for sustainable cultural transformation.

Key Takeaways:

A special feature: During the session, participants will actively experience how safety culture can be “measured” in real time, just like in a live workshop.

- Theory & Concepts: Understand the foundations and key principles of an effective safety culture
- Safety Culture State Review (SCSR): Learn how to apply the SCSR concept to evaluate and strengthen your safety culture using internal resources



4.30 Roundtable: Discovering How to Maintain Injury & Fatality Prevention Programs to Avoid Disengagement

Join us for an interactive roundtable with three focused discussion tables exploring how to maintain momentum and impact in Serious Injury and Fatality (SIF) prevention programs over the long term. Many organisations launch successful initiatives, but sustaining engagement beyond the initial phase remains the biggest challenge. This session will dig into practical strategies for keeping programs fresh, credible, and deeply embedded in your culture.



Fuad Mahmood
Global EHS Director
Grünenthal Group

Recognising and Overcoming Program Fatigue: common signs, strategies to reignite and discovering why most SIF prevention programs lose momentum after 12–24 months



Artūras Gečys
Senior Manager, EHS
Thermo Fisher
Scientific

Building Fatality Prevention into Your Culture: proactive approaches, making prevention part of your organisational DNA and leveraging evidence-based methods to sustain credibility and impact

Leadership Visibility and Everyday Integration: Maintaining ongoing leadership focus, embedding SIF prevention into daily operations and avoiding the trap of limiting focus to safety events or audits

5.15 Chair’s Closing Remarks & End of Conference

Your European Platform to Foster New & Existing Relationships With EHS Decision-Makers Within Biopharma



Generate Commercial Opportunities with a Highly Targeted Audience:

The market is crowded with EHS and data management solutions, but few address the full spectrum of what biopharma professionals urgently need. From CSRD-ready platforms and Scope 3 reporting tools to digital work permit systems, contract management, and smart PPE tracking, there's a clear demand for innovation.



Distinguish Your Brand as an Innovator in an Over-Saturated Market:


From AI-driven analytics to robotic process automation in packaging and lab safety, there's a hunger for end-to-end solutions. Showcase your platform, product, or service in front of an audience actively looking to replace outdated systems.



Connect Directly with the Experts Shaping the Future of EHS:

Brush shoulders with Global EHS Directors, Site Heads, and Safety VPs from AstraZeneca, Novo Nordisk, Regeneron, and more. These are the professionals who influence purchasing decisions, shape internal safety standards, and guide digital transformation in pharma.

Seniority of Attendees




Directors & Heads: 58%

Managers: 34%

Other: 8%

Type of Companies Attending



Statistics Taken from 2nd EHS for Biopharma East

Get Involved



Jamie Redmond
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

-  www.ehs-biopharma-europe/take-part/register
-  Tel: +44 (0)20 3141 8700
-  Email: info@hansonwade.com



DISCOVER how leading biopharma companies are redefining EHS through AI, advanced hygiene standards, and human-centred safety. Explore how AstraZeneca, Regeneron, and Takeda are using digital tools, automation, and predictive analytics to drive safer, smarter lab and GMP operations.



BUILD strategies to solve today's toughest EHS compliance challenges. From novel modalities to PFAS and toxicology alignment, gain practical insights through real-world case studies and hands-on workshops.



ENGAGE with 80+ EHS leaders and benchmark with the best in biopharma. Connect with global decision-makers in high-impact networking, roundtables, and debates to share ideas and shape the future of EHS.

EHS Professionals Pricing (Drug Developers, CDMO & CROs)	Register & Pay By Friday, 1 August	On the Door Price
Conference + Workshop Day	€2,646	€3,346
Conference Only	€1,499	€2,199

EHS Products, Services & Consultancies Pricing	Register & Pay By Friday, 1 August	On the Door Price
Conference + Workshop Day	€3,646	€4,767
Conference Only	€2,499	€2,999

To be eligible for this price, the group or individual must be an EHS Professional from a biotech or pharma company, CDMO or CRO, other non-solution providing companies may also qualify for this rate. Companies that provide solutions to EHS Professionals do not qualify for this rate. Academic Institutions or Not-for-Profit organisations may be eligible for a discounted rate - Email us at info@hansonwade.com for more information on attending.

If you are a UK or EU-based company, you may be subject to 19% VAT in addition to the price advertised. If you qualify for a reverse charge, you will have the option to provide your VAT number and the charge will be automatically deducted at checkout.

Team Discounts***

- 10% discount – 3 Attendees
- 15% discount – 4 Attendees
- 20% discount – 5+ Attendees

***Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com



Venue

Raddison Blu Hotel, Frankfurt
Franklinstrasse 65, Frankfurt, Germany, 60486
www.radissonhotels.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organisation can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom



+44 (0)20 3141 8700 @ info@hansonwade.com

www.ehs-biopharma-europe.com [Prioritize EHS](#)



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE